
|Articles|December 15, 2002
Three other glaucoma trials addressing IOP and visual field damage:
This study was designed to determine treatment sequences in patients whose advanced glaucoma was not able to be adequately controlled with maximum medical therapy.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Harrow completes acquisiton of Melt Pharmaceuticals
2
Coave Therapeutics reveals lead gene therapy program, CoTx-10
3
Foundation Fighting Blindness releases 4-year RUSH2A data to public
4
Opus Genetics doses first patient in phase 1/2 clinical trial, BIRD-1, evaluating OPGx-BEST1
5


















































.png)


